Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial

Ruyuan Li, Xingyu Liu, Chunyan Song, Wei Zhang, Jiahao Liu, Xiaofei Jiao, Yang Yu, Shaoqing Zeng, Jianhua Chi, Yingjun Zhao, Guanchen Ma, Yabing Huo, Ming Li, Zikun Peng, Guiling Li, Jie Jiang, Qing-Lei Gao, Ruyuan Li, Xingyu Liu, Chunyan Song, Wei Zhang, Jiahao Liu, Xiaofei Jiao, Yang Yu, Shaoqing Zeng, Jianhua Chi, Yingjun Zhao, Guanchen Ma, Yabing Huo, Ming Li, Zikun Peng, Guiling Li, Jie Jiang, Qing-Lei Gao

Abstract

Background: Ovarian clear cell carcinoma (OCCC) has an abysmal prognosis with a median overall survival (OS) of 25.3 months because of a low response to chemotherapy. The 5-year disease-specific survival rate after recurrence is 13.2%, with more than two-thirds of the patients dying within a year. Therefore, it is urgent to explore new therapeutic options for OCCC. Based on the characteristic immune-suppressive tumour microenvironment derived from the gene expression profile of OCCC, the combination of immunoantiangiogenesis therapy might have certain efficacy in recurrent/persistent OCCC. This trial aims to evaluate the efficacy and safety of sintilimab and bevacizumab in patients who have failed platinum-containing chemotherapy with recurrent or persistent OCCC.

Method and analysis: In this multicentre, single-arm, open-label, investigator-initiated clinical trial, 38 patients will be assigned to receive sintilimab 200 mg plus bevacizumab 15 mg/kg every 3 weeks. The eligibility criteria include histologically diagnosed patients with recurrent or persistent OCCC who have been previously treated with at least one-line platinum-containing chemotherapy; patients with Eastern Cooperative Oncology Group (ECOG) performance status 0-2 with an expected survival greater than 12 weeks. The exclusion criteria include patients previously treated with immune checkpoint inhibitor and patients with contraindications of bevacizumab and sintilimab. The primary endpoint is the objective response rate. The secondary endpoints are progression-free survival, time to response, duration of response, disease control rate, OS, safety and quality of life. Statistical significance was defined as p<0.05.

Ethics and dissemination: This trial was approved by the Research Ethics Commission of Tongji Medical College of Huazhong University of Science and Technology (2020-S337). The protocol of this study is registered at www.

Clinicaltrials: gov. The trial results will be published in peer-reviewed journals and at conferences.

Trial registration number: NCT04735861; Clinicaltrials. gov.

Keywords: gynaecological oncology; immunology; therapeutics.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Approximately 38 patients who have failed platinum-containing chemotherapy with recurrent or persistent ovarian clear cell carcinoma will be assigned to receive sintilimab 200 mg plus bevacizumab 15 mg/kg every 3 weeks. The administration of bevacizumab is up to 22 cycles and sintilimab up to 2 years. Treatment is given until confirmed progression, death, unacceptable toxicity or any other protocol-specified criterion for withdrawal, whichever occurs first. The primary endpoint of this study is the objective response rate, which is defined as the proportion of patients with complete response (CR) and partial response (PR) assessed by the investigator in accordance with the RECIST 1.1 criteria. ECOG, Eastern Cooperative Oncology Group; RECIST1.1, Solid Tumor Response Assessment Standard 1.1.

References

    1. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin 2019;69:280–304. 10.3322/caac.21559
    1. Torre LA, Trabert B, DeSantis CE, et al. . Ovarian cancer statistics, 2018. CA Cancer J Clin 2018;68:284–96. 10.3322/caac.21456
    1. Ma J, Jemal A, Fedewa SA, et al. . The American Cancer Society 2035 challenge goal on cancer mortality reduction. CA Cancer J Clin 2019;69:351–62. 10.3322/caac.21564
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34. 10.3322/caac.21551
    1. The International Agency for Research on Cancer . Global cancer statistics, 2021. Available: [Accessed Mar 2021].
    1. Kajiyama H, Shibata K, Mizuno M, et al. . Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. Int J Gynecol Cancer 2012;22:801–6. 10.1097/IGC.0b013e3182540145
    1. Sugiyama T, Kamura T, Kigawa J, et al. . Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584–9.
    1. Takano M, Sugiyama T, Yaegashi N, et al. . Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan clear cell carcinoma study. Int J Gynecol Cancer 2008;18:937–42. 10.1111/j.1525-1438.2007.01158.x
    1. Takahashi K, Takenaka M, Kawabata A, et al. . Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma. Int J Clin Oncol 2020;25:425–31. 10.1007/s10147-020-01625-w
    1. Yamaguchi K, Mandai M, Oura T, et al. . Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010;29:1741–52. 10.1038/onc.2009.470
    1. Tsuchiya A, Sakamoto M, Yasuda J, et al. . Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003;163:2503–12. 10.1016/s0002-9440(10)63605-x
    1. Oda K, Hamanishi J, Matsuo K, et al. . Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management. Gynecol Oncol 2018;151:381–9. 10.1016/j.ygyno.2018.09.001
    1. Peng J, Hamanishi J, Matsumura N, et al. . Chemotherapy induces programmed cell Death-Ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 2015;75:5034–45. 10.1158/0008-5472.CAN-14-3098
    1. Nishio H, Yaguchi T, Sugiyama J, et al. . Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor. Br J Cancer 2014;110:2965–74. 10.1038/bjc.2014.251
    1. Yaguchi T, Kawakami Y. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol 2016;28:393–9. 10.1093/intimm/dxw030
    1. Anglesio MS, George J, Kulbe H, et al. . IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011;17:2538–48. 10.1158/1078-0432.CCR-10-3314
    1. Hamanishi J, Mandai M, Ikeda T, et al. . Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015;33:4015–22. 10.1200/JCO.2015.62.3397
    1. Matulonis UA, Shapira-Frommer R, Santin AD, et al. . Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol 2019;30:1080–7. 10.1093/annonc/mdz135
    1. Zamarin D, Burger RA, Sill MW, et al. . Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J Clin Oncol 2020;38:1814–23. 10.1200/JCO.19.02059
    1. Chan JK, Brady W, Monk BJ, et al. . A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol 2018;150:247–52. 10.1016/j.ygyno.2018.05.029
    1. Konstantinopoulos PA, Brady WE, Farley J, et al. . Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). Gynecol Oncol 2018;150:9–13. 10.1016/j.ygyno.2018.04.572
    1. Lheureux S, Tinker A, Clarke B, et al. . A clinical and molecular phase II trial of oral ENMD-2076 in ovarian clear cell carcinoma (OCCC): a study of the princess margaret phase II consortium. Clin Cancer Res 2018;24:6168–74. 10.1158/1078-0432.CCR-18-1244
    1. Stany MP, Vathipadiekal V, Ozbun L, et al. . Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 2011;6:e21121. 10.1371/journal.pone.0021121
    1. Ricketts CJ, De Cubas AA, Fan H, et al. . The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep 2018;23:313–26. 10.1016/j.celrep.2018.03.075
    1. Wiegand KC, Shah SP, Al-Agha OM, et al. . ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532–43. 10.1056/NEJMoa1008433
    1. Itamochi H, Oishi T, Oumi N, et al. . Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. Br J Cancer 2017;117:717–24. 10.1038/bjc.2017.228
    1. Cancer Genome Atlas Research Network . Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43–9. 10.1038/nature12222
    1. Matsumura N, Mandai M, Okamoto T, et al. . Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci 2010;101:2658–63. 10.1111/j.1349-7006.2010.01736.x
    1. Sahebjam S, Forsyth PA, Tran ND. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high grade gliomas: results from a phase 1 study. Neuro Oncol 2020.
    1. Dudek AZ, Liu LC, Gupta S, et al. . Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003. J Clin Oncol 2020;38:1138–45. 10.1200/JCO.19.02394
    1. Ren Z, Xu J, Bai Y, et al. . Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol 2021;22:977–90. 10.1016/S1470-2045(21)00252-7
    1. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. . Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001;19:1809–17. 10.1200/JCO.2001.19.6.1809
    1. Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes 2003;1:29. 10.1186/1477-7525-1-29
    1. Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med 2001;2:297–307. 10.1016/S1389-9457(00)00065-4
    1. Craig CL, Marshall AL, Sjöström M, et al. . International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381–95. 10.1249/01.MSS.0000078924.61453.FB
    1. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337–43. 10.3109/07853890109002087
    1. Kyriaki M, Eleni T, Efi P, et al. . The EORTC core quality of life questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: validity and reliability in a Hellenic sample. Int J Cancer 2001;94:135–9. 10.1002/ijc.1439
    1. Varga A, Piha-Paul S, Ott PA, et al. . Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028. Gynecol Oncol 2019;152:243–50. 10.1016/j.ygyno.2018.11.017
    1. Liu JF, Gordon M, Veneris J, et al. . Safety, clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol 2019;154:314–22. 10.1016/j.ygyno.2019.05.021
    1. Disis ML, Taylor MH, Kelly K, et al. . Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian cancer: phase 1B results from the javelin solid tumor trial. JAMA Oncol 2019;5:393–401. 10.1001/jamaoncol.2018.6258
    1. McGrail DJ, Pilié PG, Rashid NU, et al. . High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 2021;32:661–72. 10.1016/j.annonc.2021.02.006
    1. Lin Y-C, Wen K-C, Sung P-L, et al. . Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report. J Ovarian Res 2020;13:143. 10.1186/s13048-020-00751-3
    1. Gallego A, Ramon-Patino J, Brenes J, et al. . Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma? Clin Transl Oncol 2021;23:536–42. 10.1007/s12094-020-02446-z
    1. Gabrilovich DI, Chen HL, Girgis KR, et al. . Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096–103. 10.1038/nm1096-1096
    1. Ohm JE, Gabrilovich DI, Sempowski GD, et al. . VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003;101:4878–86. 10.1182/blood-2002-07-1956
    1. Terme M, Pernot S, Marcheteau E, et al. . VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013;73:539–49. 10.1158/0008-5472.CAN-12-2325
    1. Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol 2018;9:978. 10.3389/fimmu.2018.00978
    1. Schoenfeld J, Jinushi M, Nakazaki Y, et al. . Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res 2010;70:10150–60. 10.1158/0008-5472.CAN-10-1852
    1. Tian L, Goldstein A, Wang H, et al. . Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 2017;544:250–4. 10.1038/nature21724
    1. Motzer RJ, Rini BI, McDermott DF, et al. . Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20:1370–85. 10.1016/S1470-2045(19)30413-9
    1. McGregor BA, McKay RR, Braun DA, et al. . Results of a multicenter phase II study of Atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or Sarcomatoid features. J Clin Oncol 2020;38:63–70. 10.1200/JCO.19.01882
    1. Rini BI, Powles T, Atkins MB, et al. . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404–15. 10.1016/S0140-6736(19)30723-8

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe